News
The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.
8h
Zacks Investment Research on MSNBAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...
10h
Best Life on MSNCardiologist Warns About Quiet Cause of Heart Failure: “Still Flying Under the Radar”A cardiologist spotlights cardiac amyloidosis, a protein disease often mistaken for hypertension. Learn the signs and how to get screened.
Bayer’s Kerendia (finerenone) has been approved by the US Food and Drug Administration (FDA) to treat heart failure (HF) patients with left ventricular ejection fraction (LVEF) of at least 40%.
Explore more
The FDA has broadened the approved use of finerenone (Kerendia) to include treatment for heart failure, according to an ...
US FDA approves Bayer’s finerenone for new indication in patients with heart failure with left ventricular ejection fraction of ≥ 40%: Berlin Wednesday, July 16, 2025, 13:00 H ...
In a significant move, the U.S. Food and Drug Administration granted approval for Kerendia for patients with heart failure ...
Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...
Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...
Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results